Skip to main content

Advertisement

SpringerLink
Log in

SEOM clinical guidelines for the management of metastatic breast cancer 2013

  • Clinical Guides in Oncology
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Patients with metastatic breast cancer should be offered comprehensive and personalized medical attention including, but not limited to, psychosocial, supportive and symptom-related interventions. A large number of treatment options are available and several prognostic and predictive factors are useful to identify the best therapeutic options individually.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Área de Epidemiología Ambiental y Cáncer. Centro Nacional de Epidemiología. ISCIII MORTALIDAD POR CANCER Y OTRAS CAUSAS EN ESPAÑA AÑO 2011. www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/fd-epidemiologia-ambiental-y-cancer/Mortal2011.pdf.

  2. Alvarez-Lopez I, de la Haba-Rodríguez J, Ruiz-Simón A, Bellet Ezquerra M, Calvo Martínez L, García Estévez L, et al. SEOM clinical guidelines for the treatment of metastatic breast cancer. Clin Transl Oncol. 2010;12:719–23.

    Article  PubMed  Google Scholar 

  3. Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast. 2012;21:242–52.

    Article  PubMed  CAS  Google Scholar 

  4. Cardoso F, Castiglione M, ESMO Guidelines Working Group. Locally recurrent or metastatic breast cancer: ESMO. Clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;4(Suppl 2):15–8.

    Google Scholar 

  5. Ellis M, Naughton MJ, Ma CX. Treatment approach to metastatic hormone receptor-positive breast cancer: endocrine therapy. 2012. UpToDate Topic 778 Version 17.0. http://www.uptodate.com/contents/treatment-approach-to-metastatic-hormone-receptor-positive-breast-cancer-endocrine-therapy.

  6. Baselga J, Campone M, Piccart M, Burris HA III, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520–9.

    Article  PubMed  CAS  Google Scholar 

  7. Barrios C, Forbes JF, Jonat W, Conte P, Gradishar W, Buzdar A, et al. The sequential use of endocrine treatment for advanced breast cancer: where are we? Ann Oncol. 2012;23:1378–86.

    Article  PubMed  CAS  Google Scholar 

  8. Robertson JF, Lindemann JP, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study. Breast Cancer Res Treat. 2012;136:503–11.

    Article  PubMed  CAS  Google Scholar 

  9. Bergh J, Jonsson PE, Lidbrink EK, Trudeau M, Eiermann W, Brattström D, et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol. 2012;30:1919–25.

    Article  PubMed  CAS  Google Scholar 

  10. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med. 2012;367:435–44.

    Article  PubMed  CAS  Google Scholar 

  11. Johnston SR. The role of chemotherapy and targeted agents in patients with metastatic breast cancer. Eur J Cancer. 2011;47(Suppl 3):S38–47.

    Article  PubMed  CAS  Google Scholar 

  12. Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29:1252–60.

    Article  PubMed  CAS  Google Scholar 

  13. Cortes J, Calvo E, Gonzalez-Martin A, Dawood S, Llombart-Cussac A, De Mattos-Arruda L, et al. Progress against solid tumors in danger: the metastatic breast cancer example. J Clin Oncol. 2012;30:3444–7.

    Article  PubMed  CAS  Google Scholar 

  14. Oostendorp LJ, Stalmeier PF, Donders AR, van der Graaf WT, Ottevanger PB. Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review. Lancet Oncol. 2011;12:1053–61.

    Article  PubMed  CAS  Google Scholar 

  15. Montero AJ, Adams B, Diaz-Montero CM, Glück S. Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review. Expert Rev Clin Pharmacol. 2011;4:329–34.

    Article  PubMed  CAS  Google Scholar 

  16. Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011;377:914–23.

    Article  PubMed  CAS  Google Scholar 

  17. Nielsen DL, Kümler I, Palshof JA, Andersson M. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Breast. 2013;22:1–12.

    Article  PubMed  Google Scholar 

  18. Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109–19.

    Article  PubMed  CAS  Google Scholar 

  19. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, EMILIA Study Group, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–91.

    Article  PubMed  CAS  Google Scholar 

  20. Cassinello Espinosa J, González Del Alba Baamonde A, Rivera Herrero F, Holgado Martín E; SEOM (Spanish Society of Clinical Oncology). SEOM guidelines for the treatment of bone metastases from solid tumours. Clin Transl Oncol. 2012;14:505–11.

  21. Pockaj BA, Wasif N, Dueck AC, Wigle DA, Boughey JC, Degnim AC, et al. Metastasectomy and surgical resection of the primary tumor in patients with stage IV breast cancer: time for a second look? Ann Surg Oncol. 2010;17:2419–26.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest relating to the publication of this manuscript.

Author information

Authors and Affiliations

  1. Servicio de Oncología Médica, Hospital Arnau de Vilanova, C/San Clemente, 12, 46015, Valencia, Spain

    A. Llombart Cussac

  2. Servicio de Oncología Médica, Hospital Universitario Reina Sofía, Córdoba, Spain

    J. de la Haba Rodríguez

  3. Servicio de Oncología Médica, Instituto Valenciano de Oncología, Valencia, Spain

    A. Ruiz Simón

  4. Servicio de Oncología Médica, Hospital de Donostia, San Sebastián, Spain

    I. Álvarez López

  5. Servicio de Oncología Médica, Hospital General Vall d’Hebrón, Barcelona, Spain

    J. Cortés Castán

Authors
  1. A. Llombart Cussac
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. de la Haba Rodríguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Ruiz Simón
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. Álvarez López
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Cortés Castán
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Llombart Cussac.

Appendix: Clinical Guideline Working Group on behalf of the Spanish Society of Medical Oncology (SEOM) Executive Committee 2011–2013

Appendix: Clinical Guideline Working Group on behalf of the Spanish Society of Medical Oncology (SEOM) Executive Committee 2011–2013

Juan Jesús Cruz, Pilar Garrido, Agustí Barnadas, Pablo Borrega, Francisco Javier Barón, Elvira del Barco, Rocio García-Carbonero, Jesús Garcia-Mata, Encarnación Gonzalez, Pilar Lianes, Antonio Llombart y Fernando Rivera.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Llombart Cussac, A., de la Haba Rodríguez, J., Ruiz Simón, A. et al. SEOM clinical guidelines for the management of metastatic breast cancer 2013. Clin Transl Oncol 15, 1004–1010 (2013). https://doi.org/10.1007/s12094-013-1095-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-013-1095-0

Keywords

Search

Navigation